acetylleucyl-leucyl-norleucinal has been researched along with lovastatin in 4 studies
Studies (acetylleucyl-leucyl-norleucinal) | Trials (acetylleucyl-leucyl-norleucinal) | Recent Studies (post-2010) (acetylleucyl-leucyl-norleucinal) | Studies (lovastatin) | Trials (lovastatin) | Recent Studies (post-2010) (lovastatin) |
---|---|---|---|---|---|
321 | 0 | 53 | 4,828 | 698 | 873 |
Protein | Taxonomy | acetylleucyl-leucyl-norleucinal (IC50) | lovastatin (IC50) |
---|---|---|---|
Chain A, Antigen Cd11a (p180) | Homo sapiens (human) | 2.4 | |
3-hydroxy-3-methylglutaryl-coenzyme A reductase | Homo sapiens (human) | 0.0261 | |
Integrin beta-2 | Homo sapiens (human) | 3.09 | |
Intercellular adhesion molecule 1 | Homo sapiens (human) | 3.78 | |
Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 8.753 | |
ATP-dependent translocase ABCB1 | Homo sapiens (human) | 10 | |
Neutrophil elastase | Homo sapiens (human) | 0.027 | |
Insulin receptor | Rattus norvegicus (Norway rat) | 0.02 | |
Integrin alpha-L | Homo sapiens (human) | 3.09 | |
Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 8.753 | |
Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.02 | |
3-hydroxy-3-methylglutaryl-coenzyme A reductase | Rattus norvegicus (Norway rat) | 0.0529 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (25.00) | 18.2507 |
2000's | 3 (75.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
Choi, YH; Henkart, PA; Hwang, SG; Jang, JS; Lee, J; Lee, SJ; Maki, M; Nguyen, PM; Takano, E; Trepel, JB; Wu, ML | 1 |
Aboushadi, N; Gentile, A; Jessani, N; Krisans, SK; Shackelford, JE | 1 |
Avner, R; Doolman, R; Harats, D; Ravid, T; Roitelman, J | 1 |
4 other study(ies) available for acetylleucyl-leucyl-norleucinal and lovastatin
Article | Year |
---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Posttranslational regulation of the retinoblastoma gene family member p107 by calpain protease.
Topics: Acetylcysteine; Amino Acid Chloromethyl Ketones; Bucladesine; Calpain; Cyclin B; Cyclin B1; Cysteine Proteinase Inhibitors; Dipeptides; Fluorouracil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ketones; Leupeptins; Lovastatin; Nuclear Proteins; Protein Processing, Post-Translational; Retinoblastoma Protein; Retinoblastoma-Like Protein p107; Tumor Cells, Cultured | 1999 |
Characterization of peroxisomal 3-hydroxy-3-methylglutaryl coenzyme A reductase in UT2 cells: sterol biosynthesis, phosphorylation, degradation, and statin inhibition.
Topics: Acetic Acid; Acetyl-CoA C-Acetyltransferase; Adenosine Triphosphate; Animals; Carbon Radioisotopes; Cell Cycle; Cell Survival; CHO Cells; Cholesterol; Clone Cells; Cricetinae; Deuterium Oxide; Enzyme Activation; Fatty Acids, Unsaturated; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxymethylglutaryl-CoA Synthase; Lactones; Leupeptins; Lovastatin; Mevalonic Acid; Peroxisomes; Phosphorylation; Simvastatin; Tritium | 2000 |
The ubiquitin-proteasome pathway mediates the regulated degradation of mammalian 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
Topics: Animals; beta-Galactosidase; Bridged Bicyclo Compounds, Heterocyclic; Cell Line; Cholesterol; Cricetinae; Cycloheximide; Cysteine Proteinase Inhibitors; Farnesyl-Diphosphate Farnesyltransferase; Humans; Hydroxycholesterols; Hydroxymethylglutaryl CoA Reductases; Leupeptins; Lovastatin; Oligopeptides; Peptide Hydrolases; Precipitin Tests; Proteasome Endopeptidase Complex; Recombinant Fusion Proteins; Tricarboxylic Acids; Ubiquitins | 2000 |